The significance of simultaneous assessment of both mutations is due to the fact that most studies show that a favorable prognostic value of NPM1 mutations is only valid in the absence of FLT3/ITD mutations.10, 11, 31 It has been shown that a NPM1Pos/FLT3-ITDNeg mutations profile represents an independent predictor for a favorable outcome in younger AML patients, especially in those without cytogenetic abnormalities.10 This evidence concerns the gene FLT3 and acute myeloid leukemia.